No writing assistance was utilized in the production of this manuscript. Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting ...

Recent studies have explored the effectiveness of switching to a two-drug regimen, specifically dolutegravir ... than 50 copies of HIV RNA per milliliter of blood. Integrase Strand-Transfer ...

Real-world analyses have confirmed the efficacy of the 2-drug regimen of dolutegravir and lamivudine in treating HIV, confirming phase 3 testing results. HIV causes immunosuppression because the ...

Generally, drugs from two (or sometimes three) classes are combined to ensure a combined attack on HIV. The four main classes, which most people are treated with, target one of three viral proteins ...

when ViiV – a joint venture majority owned by GlaxoSmithKline alongside Pfizer and Shionogi – accused Gilead of infringing its patents on HIV integrase inhibitor dolutegravir. The dispute ...